2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

Citations Over TimeTop 1% of 2021 papers

Abstract

CV Cardiovascular CYP Cytochrome P (CYP) Unfractionated heparin ULN Upper limit of normal VENTURE-AF Active-controlled multi-center study with blind-adjudication designed to evaluate the safety of uninterrupted Rivaroxaban and uninterrupted vitamin K antagonists in subjects undergoing catheter ablation for non-valvular Atrial Fibrillation VHD Valvular heart disease VKA Vitamin K antagonist VTE Venous thromboembolic event WOEST What is the Optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary stenting X-VeRT Explore the efficacy and safety of once daily oral rivaroxaban for the prevention of cardiovascular events in patients with non-valvular atrial fibrillation scheduled for cardioversion a SmPC: 110 mg BID if age > _80 years, concomitant verapamil (both based on pharmacokinetics/pharmacodynamics analyses; not studied in this setting). b Not specifically studied, follow-up data available up to 12 months in phase III trial. c SmPc: 20 mg QD in patients at high risk of recurrence. 2021 EHRA Practical Guide on the use of NOACs AF, atrial fibrillation; CrCl, creatinine clearance; INR, international normalized ratio; NOAC, non-vitamin K antagonist oral anticoagulant; NSAID, non-steroidal anti-inflammatory drug; TIA, transient ischaemic attack; VKA, vitamin K antagonist. For frequency of visits: see Figure 3.

Related Papers

• → Rivaroxaban in the Treatment of PICC-associated Upper Extremity Venous Thrombosis(2017)31 cited
• → Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries(2024)3 cited
• → Is the use of warfarin becoming obsolete?(2021)1 cited
• → Abstract P005: Comparative Effectiveness of Rivaroxaban versus Warfarin for the Treatment of Patients with Non-valvular Atrial Fibrillation(2016)
• → ACUTE LOWER GASTROINTESTINAL BLEEDING IN PATIENTS TREATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS COMPARED WITH WARFARIN IN CLINICAL PRACTICE: CHARACTERISTICS AND CLINICAL OUTCOME.(2017)